NCT02092181View on ClinicalTrials.gov

A Pilot Study of Mirabegron and Behavioral Modification Including Pelvic Floor Exercise for Overactive Bladder in Parkinson's Disease (MAESTRO)

PHASE4CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

March 31, 2014

Primary Completion Date

July 1, 2018

Study Completion Date

July 1, 2018

Conditions
Parkinsons Disease
Interventions
DRUG

Mirabegron

25 mg po daily for 32-40 days. Following up-titration to 50 mg po daily. This is pending no adverse events on the 25 mg dose.

DRUG

Placebo

Placebo 25 mg po daily. Following up-titration to 50 mg po daily. This is pending no adverse events on the 25 mg dose.

Trial Locations (1)

98034

Evergreenhealth Booth Gardner Parkinsons Care Center, Kirkland

All Listed Sponsors
collaborator

Astellas Pharma US, Inc.

INDUSTRY

lead

Daniel Burdick, MD

INDIV

NCT02092181 - A Pilot Study of Mirabegron and Behavioral Modification Including Pelvic Floor Exercise for Overactive Bladder in Parkinson's Disease (MAESTRO) | Biotech Hunter | Biotech Hunter